Trial Profile
Efficacy and Safety Evaluation of Rifaximin Combined Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 29 Dec 2021 Planned End Date changed from 1 Apr 2020 to 1 Dec 2023.
- 29 Dec 2021 Planned primary completion date changed from 1 Apr 2020 to 1 Jul 2023.
- 25 Sep 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.